University of California, San Diego bioengineer Karen Christman's new injectable hydrogel, which is designed to repair damaged cardiac tissue following a heart attack, has been licensed to San Diego-based startup Ventrix, Inc, which is planning the first human clinical trials of the technology. Christman is a co-founder of Ventrix.
